Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | CDK14 | O94921 | 1/20 | 0.36 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.36 |
| ▸ | PPIA | P62937 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307579 | 0.78 | TAS1R3 (0.69) | TAS1R3TAS1R1TAS1R2RAB9ATYK2 | |
| SCHEMBL7311576 | 0.68 | RAB9A (0.69) | MAPTNPC1GLAHPGDNOTUM | |
| SCHEMBL25503925 | 0.66 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2TYK2 | |
| SCHEMBL14275542 | 0.66 | GLA (0.57) | MAPTNPC1GLAHPGDNOTUM | |
| SCHEMBL702131 | 0.65 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20147603 | 0.64 | RET (0.45) | TAS1R3TAS1R1TAS1R2TYK2 | |
| SCHEMBL20068948 | 0.64 | ALDH1A1 (0.48) | TAS1R3TAS1R1TAS1R2MAPTPPIA | |
| SCHEMBL1307512 | 0.64 | CYP2C19 (0.56) | TAS1R3TAS1R1TAS1R2NPC1HPGD | |
| SCHEMBL13198827 | 0.63 | NPC1 (0.67) | MAPTNPC1GLAHPGDRAB9A | |
| SCHEMBL14197783 | 0.63 | NPC1 (0.57) | NPC1GLAHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | CDK1, CDK3, CDK2 | TAS1R3 3976/4885TAS1R1 4074/4885TAS1R2 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.